Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
B. lactis (BB-12 / HN019) vs L. rhamnosus GG: L. rhamnosus GG has the stronger overall evidence (6 vs 6/10); they're alternatives for improve digestion — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
L. rhamnosus GG wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both B. lactis (BB-12 / HN019) and L. rhamnosus GG have evidence — compare verdict strength side-by-side.
1-10 billion CFU daily for BB-12 (1 billion is enough); 10-20 billion CFU daily for HN019 if transit is the goal
Any time of day
Capsule or sachet standardized to a named strain (BB-12 or HN019)
10-20 billion CFU (1-2 x 10^10) daily. A meta-analysis in children with acute gastroenteritis found LGG effective at 10 billion CFU/day or more, and borderline below that.
Any time of day
Capsule standardized to ATCC 53103
2 weeks
4 weeks
n/a
n/a
During the antibiotic course
During hospital stay
n/a
n/a
Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults.
Scand J Gastroenterol (2011) · Rct · n=100
Whole-gut transit fell 49 to 21 hours on high dose (p<0.001) and 60 to 41 hours on low dose (p=0.01); placebo unchanged
Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial.
JAMA Netw Open (2024) · Rct · n=229
Primary outcome (change in complete spontaneous bowel movements per week): +0.80 with HN019 vs +0.66 placebo — no difference
Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial.
Gut Microbes (2018) · Rct · n=228
No significant differences vs placebo in the primary outcome (colonic transit time) or any secondary outcome
Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children.
N Engl J Med (2018) · Rct · n=971
Primary outcome (modified Vesikari score >=9 within 14 days): 11.8% with LGG vs 12.6% placebo; RR 0.96 (0.68-1.35), P=0.83
Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults.
Aliment Pharmacol Ther (2015) · Meta analysis
Antibiotic-associated diarrhea fell from 22.4% to 12.3%; RR 0.49 (0.29-0.83) pooled across 11 RCTs, n=1,308 (12 RCTs, n=1,499 included overall)
Probiotics for treating acute infectious diarrhoea.
Cochrane Database Syst Rev (2020) · Meta analysis
In studies at low risk of bias, no difference in diarrhea lasting >=48 hours (RR 1.00, 0.91-1.09; moderate certainty)
L. rhamnosus GG has a higher evidence score (6/10 vs 6/10) and wins in 1 of 3 categories.
For improve digestion, L. rhamnosus GG has a higher relevance score (72 vs 68).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.